Congenital Hypertrophy of the Retinal Pigment Epithelium

Congenital hypertrophy of the retinal pigment epithelium (CHRPE) is a benign, congenital overgrowth (hamartoma) of the retinal pigment epithelial (RPE) layer of the eye. On exam, it appears as a flat, well‑circumscribed, pigmented lesion—often round or oval—with sharply demarcated borders. Lesions can contain pale “lacunae” (small areas of RPE atrophy) and vary in color from light gray to jet black. CHRPE is typically discovered incidentally during a routine dilated fundus examination, as it rarely causes any symptoms in its solitary form. EyeWikiWikipedia

Congenital Hypertrophy of the Retinal Pigment Epithelium (CHRPE) is a benign, flat, pigmented lesion of the retinal pigment epithelium present from birth. Microscopically, it represents a hamartomatous overgrowth of RPE cells, typically measuring 0.5–3 mm in diameter, with well-demarcated margins and uniform pigmentation. CHRPE lesions are most often solitary but can occur in clusters (“bear tracks”), especially in patients with familial adenomatous polyposis (FAP), where multiple lesions may signal systemic risk EyeWiki. These lesions generally remain stable over time and do not affect vision unless complicated by secondary changes such as choroidal neovascularization (CNV) New York Eye Cancer Center.

Types

CHRPE occurs in three recognized variants:

• Solitary (Unifocal) CHRPE: A single, flat, pigmented lesion, usually peripheral, with smooth, well‑defined borders.

• Grouped (Multifocal) CHRPE (“Bear Tracks”): Multiple, small, discrete pigmented spots clustered in one quadrant, resembling animal footprints.

• Atypical CHRPE: Irregularly shaped, often bilateral lesions—fisheye, comma, or pisciform shapes—associated with systemic disease (see below). EyeWiki

---

Causes and Associations

While CHRPE is congenital and the exact trigger for RPE overgrowth remains unknown in most cases, research has identified several contributing factors and genetic associations:

1. Idiopathic Reactive Hyperplasia
   Many CHRPE lesions arise without any identifiable cause, representing spontaneous overgrowth of RPE cells. Review of Optometry

2. Congenital Hamartoma Formation
   CHRPE is classified as a hamartoma—an excess of normal tissue arranged in an abnormal fashion—originating during embryonic development of the eye. EyeWiki

3. Somatic Mosaicism in RPE Precursors
   “Bear tracks” grouped CHRPE lesions mirror patterns of cutaneous pigment mosaicism, suggesting that somatic cell clones of RPE precursors proliferate along embryonic lines of Blaschko. PubMed

4. APC Gene Mutation
   Mutations in the adenomatous polyposis coli (APC) tumor suppressor gene can manifest in the retina as atypical CHRPE lesions. EyeWiki

5. Familial Adenomatous Polyposis (FAP)
   FAP is an autosomal‑dominant syndrome caused by germline APC mutations; patients often develop multiple bilateral CHRPE spots before colonic polyps appear. EyeWiki

6. Gardner Syndrome
   A variant of FAP featuring extracolonic manifestations (osteomas, desmoid tumors) in addition to CHRPE; CHRPE can be the earliest phenotypic marker. Review of Optometry

7. Heritable Predisposition
   Familial clustering of CHRPE outside of FAP suggests additional genetic factors influencing RPE cell growth. Clinical Gate

8. Embryonic Developmental Error
   Aberrant differentiation or migration of neuroectodermal (RPE) cells during optic cup formation may underlie focal RPE hyperplasia. PubMed

9. Excess Melanosome Accumulation
   CHRPE cells display unusually dense cytoplasmic pigmentation from melanosomes, reflecting dysregulated pigment granule synthesis or clearance. ScienceDirect

10. Local Dysregulation of Proliferation Pathways
    As a hamartoma, CHRPE likely involves focal disruption of cell‑cycle control—overactive growth signals or inadequate apoptosis—in RPE. Nature

11. Epigenetic Modifications (Hypothetical)
    DNA methylation or histone changes affecting genes that regulate RPE proliferation may play a role, though data are lacking. (unconfirmed)

12. Intrauterine Environmental Influences (Hypothetical)
    Maternal factors—such as transient hypoxia or inflammation—could theoretically perturb RPE development in utero. (unconfirmed)

13. Altered Growth Factor Signaling (Hypothetical)
    Imbalances in EGF, TGF‑β, or other cytokines during eye development may trigger focal RPE overgrowth. (unconfirmed)

14. Chromosomal Mosaicism (Hypothetical)
    Early embryonic chromosomal errors might produce distinct RPE cell clones with proliferative advantages. (unconfirmed)

15. Somatic Mutations in Other Tumor Suppressor Genes (Hypothetical)
    Beyond APC, sporadic post‑zygotic mutations in genes regulating RPE cell growth may contribute to lesion formation. (unconfirmed)

Note: Causes 1–10 have supportive literature; items 11–15 remain speculative with limited direct evidence.

---

Symptoms

CHRPE is most often asymptomatic, but in certain situations lesions can produce visual disturbances:

1. No Ocular Symptoms
   The vast majority of CHRPE lesions cause no discomfort or visual complaints and are discovered incidentally. EyeWiki

2. Blurred Vision
   When a lesion extends into or very near the fovea, patients may notice general blurriness in their central vision. EyeWiki

3. Reduced Visual Acuity
   Documented foveal involvement has led to measurable drops in best‑corrected visual acuity on eye chart testing. EyeWiki

4. Central Scotoma
   Loss of photoreceptors overlying a CHRPE lesion can produce a localized blind spot in the central visual field. ScienceDirect

5. Metamorphopsia
   Distortion or waviness of straight lines on an Amsler grid may occur if the macula is secondarily affected by gliosis or edema. EyeWiki

6. Photopsia
   Occasional flashes of light can arise from serous retinal detachment in rare nodular or complicated cases. EyeWiki

7. Distorted Vision
   Premacular gliosis over a pigmented lesion can lead to image distortion even without frank fluid accumulation. EyeWiki

8. Peripheral Field Defect
   Confrontation testing may reveal peripheral blind spots that correspond to more eccentric CHRPE lesions. ScienceDirect

9. Color Perception Changes
   Involvement of the macula may subtly affect color discrimination, though this is uncommon. (inferred)

10. Visual Disturbances from CNV
    Choroidal neovascularization complicating a CHRPE lesion can cause metamorphopsia, scotoma, or hemorrhage. EyeWiki

---

Diagnostic Tests:

Below are the key investigations used to diagnose and monitor CHRPE, grouped by category:

Physical Exam

1. Best‑Corrected Visual Acuity (BCVA)
   Standard eye chart testing to quantify any reduction in central vision if the macula is involved. EyeWiki

2. Confrontation Visual Field Testing
   A quick, in‑office screen for peripheral visual field defects matching lesion location. Wikipedia

3. Color Vision Testing
   Assesses color discrimination, useful when central CHRPE lesions threaten macular function. Retina Consultants of Texas

4. Pupillary Light Reflex Examination
   Ensures no afferent pupillary defect, which would be unexpected given CHRPE’s localized nature.

Manual/Ophthalmoscopic Tests

5. Amsler Grid
   A simple grid test for detecting metamorphopsia or central scotomas caused by macular involvement. BMJ Case Reports

6. Direct Ophthalmoscopy
   Hand‑held exam to visualize the lesion’s color, size, and margins. Local Eyes Optometry

7. Indirect Ophthalmoscopy
   Provides a wide‑field view of the retina, crucial for mapping multifocal CHRPE. PMC

8. Slit‑Lamp Biomicroscopy with Fundus Lens
   High‑magnification examination of the lesion’s surface—lacunae, drusen, or irregularities. New York Eye Cancer Center

Laboratory and Pathology

9. APC Genetic Testing
   Molecular analysis for germline APC mutations in patients with multiple or atypical lesions. EyeWiki

10. Lesion Biopsy with Histopathology
    Rarely performed—confirms RPE cell hypertrophy, abundant melanin, and benign cytology. EyeWiki

11. Immunohistochemical Stains
    Melanin‑specific and cytokeratin markers differentiate RPE cells from other pigmented tumors.

Electrodiagnostic Tests

12. Full‑Field Electroretinography (ffERG)
    Assesses global retinal function to exclude diffuse retinal disease; CHRPE itself typically spares overall ERG responses. EyeWiki

13. Multifocal Electroretinography (mfERG)
    Maps localized retinal electrical activity, pinpointing functional deficits over the lesion. NCBI

14. Electrooculography (EOG)
    Measures RPE function by tracking changes in standing corneo‑retinal potential; may show subtle RPE dysfunction. USF Health

15. Visual Evoked Potential (VEP)
    Tests post‑retinal visual pathways; reserved for cases with atypical visual complaints. USF Health

Imaging Modalities

16. Color Fundus Photography
    High‑resolution documentation of lesion appearance and monitoring for changes over time. EyeWiki

17. Fundus Autofluorescence (FAF)
    Highlights areas of RPE health and atrophy by detecting lipofuscin fluorescence—CHRPE appears markedly hypo‑autofluorescent. EyeWiki

18. Optical Coherence Tomography (OCT)
    Cross‑sectional imaging reveals RPE thickening, overlying photoreceptor loss, and any subretinal fluid. EyeWiki

19. OCTA (OCT Angiography)
    Noninvasive view of retinal/choroidal vessels to rule out neovascular membranes adjacent to CHRPE. EyeWiki

20. Fluorescein Angiography (FA)
    Dynamic imaging shows the CHRPE lesion as persistently dark (hypofluorescent) due to dense pigment blocking choroidal fluorescence. EyeWiki

Non-Pharmacological Management Strategies

Because CHRPE is benign and non-progressive, no specific “cure” is needed; management focuses on monitoring and supporting overall retinal health. The following measures—grouped into Exercise Therapies, Mind-Body Techniques, and Educational Self-Management—can optimize ocular circulation, reduce oxidative stress, and empower patients in self-care.

A. Exercise Therapies

Intro: Physical activity enhances systemic and ocular blood flow, potentially supporting RPE cell metabolism and health PubMedmahajanlab.stanford.edu.

1. Ocular Motility Exercises: Gaze-holding and saccade drills improve extraocular muscle coordination, promoting microcirculatory flow to the retina.

2. Pursuit Training: Tracking slow moving objects horizontally and vertically enhances retinal perfusion by rhythmic ocular muscle contractions.

3. Accommodation Workouts: Alternating near-far focusing exercises stimulate ciliary muscle activity, indirectly benefiting choroidal circulation.

4. Contrast-Sensitivity Drills: Using graded-contrast charts strengthens visual pathways, supporting metabolic demands of photoreceptors.

5. Binocular Fusion Tasks: Convergence and divergence exercises optimize binocular alignment, reducing strain and improving retinal oxygenation.

6. Yoga-Based Stretching: Gentle neck and shoulder stretches lower cervical vascular tension, aiding ocular venous drainage.

7. Aerobic Conditioning: Brisk walking or cycling for 30 minutes increases overall cardiovascular health, thereby improving retinal perfusion.

B. Mind-Body Techniques

Intro: Stress reduction via mind-body practices can lower intraocular pressure (IOP) and oxidative stress, supporting RPE integrity PubMedPubMed.

1. Guided Meditation: Focused breathing exercises reduce sympathetic tone, leading to modest IOP reductions.
2. Progressive Muscle Relaxation: Systematic tensing and relaxing of muscle groups decreases cortisol, mitigating oxidative damage in ocular tissues.
3. Mindfulness-Based Stress Reduction: Body-scan meditations enhance autonomic balance, improving ocular perfusion.
4. Yoga Nidra: Deep-relaxation protocol that has been associated with lower systemic blood pressure, indirectly benefiting choroidal circulation.
5. Biofeedback Training: Real-time monitoring of eye temperature or IOP empowers users to self-regulate stress responses.
6. Tai Chi: Flowing postures combine gentle exertion with deep breathing, improving microvascular health.
7. Guided Imagery: Visualization of healthy vision fosters relaxation and may support neuro-ophthalmic resilience.

C. Educational Self-Management

Intro: Patient education on CHRPE and general eye health fosters early recognition of changes and ensures appropriate follow-up EyeWikicollege-optometrists.org.

1. Lesion Photography Training: Teaching patients to take standardized fundus photographs enables at-home monitoring for subtle changes.
2. Symptom Diary Keeping: Recording visual disturbances (floaters, flashes) helps detect complications early.
3. Genetic Counseling for FAP: In cases of multiple CHRPE, understanding familial risk guides colonoscopy screening.
4. Nutrition Workshops: Structured classes on ocular-healthy diets encourage antioxidant-rich food choices.
5. Vision Rehabilitation Seminars: Learning low-vision adaptive strategies prepares patients for any rare vision changes.
6. Peer Support Groups: Sharing experiences reduces anxiety around monitoring and enhances adherence to follow-up schedules.

---

Pharmacological Agents

No drugs target CHRPE itself, as it is a benign congenital lesion NCBI. However, if a CHRPE lesion is complicated by secondary choroidal neovascularization (CNV), the following agents—aimed at controlling CNV—may be used:

1. Ranibizumab (Lucentis)

   • Class: Anti-VEGF monoclonal antibody fragment

   • Dosage: 0.5 mg intravitreal injection once monthly

   • Administration: Intravitreal injection under topical anesthesia

   • Side Effects: Endophthalmitis, retinal detachment, transient IOP elevation Verywell HealthEyeWiki

2. Bevacizumab (Avastin)

   • Class: Anti-VEGF monoclonal antibody

   • Dosage: 1.25 mg intravitreal injection every 4–6 weeks

   • Side Effects: Ocular hemorrhage, infection, IOP spikes EyeWikiWikipedia

3. Aflibercept (Eylea)

   • Class: VEGF-Trap fusion protein

   • Dosage: 2 mg intravitreal injection every 4 weeks for 3 months, then every 8 weeks

   • Side Effects: Conjunctival hemorrhage, eye pain, hypertension Drugs.com

4. Pegaptanib (Macugen)

   • Class: Anti-VEGF aptamer

   • Dosage: 0.3 mg intravitreal injection every 6 weeks

   • Side Effects: Endophthalmitis, floaters, IOP rise Verywell Health

5. Verteporfin (Visudyne)

   • Class: Photosensitizer for photodynamic therapy

   • Dosage: 6 mg/m² IV infusion followed by 689 nm laser activation 15 minutes later; repeat every 3 months if needed

   • Side Effects: Photosensitivity, injection site reactions Wikipedia

6. Dexamethasone Implant (Ozurdex)

   • Class: Sustained-release corticosteroid

   • Dosage: 0.7 mg intravitreal implant every 3–6 months

   • Side Effects: Cataract progression, IOP elevation Verywell Health

7. Triamcinolone Acetonide

   • Class: Corticosteroid injection

   • Dosage: 4 mg/0.1 mL intravitreal injection (off-label)

   • Side Effects: Elevated IOP, cataract Verywell Health

8. Fluocinolone Acetonide Implant (Iluvien)

   • Class: Intravitreal corticosteroid implant

   • Dosage: 0.19 mg implant with up to 36 months release

   • Side Effects: High rate of cataract and glaucoma Verywell Health

9. Faricimab (Vabysmo)

   • Class: Bispecific anti-VEGF/Ang-2 antibody

   • Dosage: 6 mg intravitreal injection monthly × 4, then every 8 weeks

   • Side Effects: Endophthalmitis, conjunctival hemorrhage Medscape ReferenceGene

10. Brolucizumab (Beovu)

• Class: Single-chain anti-VEGF antibody fragment

• Dosage: 6 mg intravitreal injection monthly × 3, then every 8–12 weeks

• Side Effects: Retinal vasculitis, occlusive events Novartis

---

 Dietary Molecular Supplements

Although no supplement can “treat” CHRPE, the following micronutrients support RPE and photoreceptor health, and may reduce oxidative stress in the retina Verywell Health:

1. Lutein (10 mg/day) – Carotenoid antioxidant; filters blue light and scavenges free radicals HealthlineDrugs.com

2. Zeaxanthin (2 mg/day) – Macular pigment component; protects against phototoxicity HealthlineDrugs.com

3. Omega-3 (DHA/EPA) (1 g/day) – Long-chain polyunsaturated fatty acids; maintain photoreceptor membrane fluidity and reduce inflammation PubMed

4. Vitamin C (500 mg/day) – Water-soluble antioxidant; regenerates other antioxidants in ocular tissues AAO

5. Vitamin E (400 IU/day) – Lipid-soluble antioxidant; prevents peroxidation of photoreceptor membranes AAO

6. Zinc (80 mg/day) – Enzyme cofactor (e.g., superoxide dismutase); supports RPE cell metabolism AAO

7. Copper (2 mg/day) – Prevents zinc-induced deficiency; cofactor for antioxidant enzymes Milton Keynes University Hospital

8. Bilberry Anthocyanins (160 mg/day) – Flavonoid antioxidants; improve ocular microcirculation PubMedMDPI

9. Ginkgo Biloba Extract (120 mg/day) – Vasodilator; enhances choroidal blood flow by PAF inhibition American Optometric Association

10. Saffron (Crocetin/Crocin) (20 mg/day) – Carotenoid antioxidant; protects against photoreceptor apoptosis and inflammation Medical News TodayMDPI

---

Regenerative (Stem-Cell-Based) Therapies

Experimental cell therapies aim to replace or support RPE function; none are yet standard of care Wikipedia:

1. hESC-Derived RPE Cell Suspension (MA09-hRPE)

   • Dose: 200 000 cells subretinal injection

   • Function: Replace dysfunctional RPE; secrete trophic factors

   • Mechanism: Engraft on Bruch’s membrane, phagocytose photoreceptor outer segments PMC

2. hESC-RPE Patch (OpRegen®)

   • Dose: Monolayer patch containing ~100 000 RPE cells

   • Function: Structural RPE replacement

   • Mechanism: Integrates on Bruch’s membrane to restore barrier and phagocytic functions Wikipedia

3. iPSC-Derived Autologous RPE

   • Dose: ~250 000 cells subretinal injection

   • Function: Patient-specific RPE replacement

   • Mechanism: Minimizes immune rejection, restores RPE physiology Wikipedia

4. MSC Intravitreal Injection

   • Dose: 1 × 10^6 mesenchymal stem cells

   • Function: Paracrine neuroprotection

   • Mechanism: Secrete anti-inflammatory and neurotrophic factors Wikipedia

5. RPE-Choroid Autograft

   • Dose: Autologous RPE-choroid patch

   • Function: Autologous tissue replacement

   • Mechanism: Preserves photoreceptor support functions of native RPE Wikipedia

6. ASP7317 (ESC-Derived RPE for Geographic Atrophy)

   • Dose: Phase Ib dose escalation (50 000–200 000 cells)

   • Function: RPE restoration in GA

   • Mechanism: Engraftment and support of photoreceptors Wikipedia

---

Surgical Interventions

Surgery is not indicated for uncomplicated CHRPE but may be considered if secondary CNV or diagnostic uncertainty arises:

1. Laser Photocoagulation

   • Procedure: Focal thermal laser to ablate neovascular membranes

   • Benefits: Prevents leakage from CNV, limits further retinal damage Verywell Health

2. Photodynamic Therapy (PDT)

   • Procedure: IV verteporfin followed by low-energy laser activation

   • Benefits: Selectively occludes CNV with minimal collateral damage EyeWiki

3. Vitrectomy with Submacular Surgery

   • Procedure: Pars plana vitrectomy and removal of subretinal CNV

   • Benefits: Direct removal of pathological membranes, potential vision stabilization Verywell Health

4. Macular Translocation

   • Procedure: Detach and rotate neurosensory retina onto healthy RPE

   • Benefits: Relocates fovea away from diseased RPE; may improve central vision in advanced cases Retina Today

5. Autologous RPE-Choroid Graft

   • Procedure: Transplant peripheral RPE-choroid tissue under fovea

   • Benefits: Restores RPE function with patient’s own tissue, reduces rejection risk Wikipedia

---

Prevention Strategies

While CHRPE is congenital and non-preventable, general ocular health measures may reduce risk of other retinal diseases and aid monitoring:

1. Annual Comprehensive Eye Exams – Early detection of changes.

2. UV-Protective Eyewear – Shields retina from UV-induced photodamage.

3. Antioxidant-Rich Diet – Fruits, vegetables, and omega-3s support RPE health Verywell Health.

4. Smoking Cessation – Lowers oxidative stress in ocular tissues.

5. Blood Pressure Control – Ensures stable choroidal perfusion.

6. Glycemic Management – Reduces risk of diabetic retinopathy.

7. Regular Aerobic Exercise – Improves systemic and ocular microcirculation.

8. Protective Eyewear in Sports – Prevents traumatic retinal injury.

9. Blue-Light Filtering Lenses – Minimizes digital eye strain and potential phototoxicity.

10. Genetic Screening for FAP – In cases of multiple CHRPE, enables timely colonoscopy.

---

When to See a Doctor

• New Visual Symptoms: Any sudden floaters, flashes, or field defects.

• Lesion Changes: Growth, color change, or development of subretinal fluid.

• Multiple Lesions: Raises concern for FAP—referral for genetic evaluation.

• Associated Discomfort: Pain, redness, or photophobia.

• Routine Monitoring: At least annually or sooner if risk factors (e.g., FAP) exist.

---

“Do’s and Don’ts” for Patients

1. Do keep a symptom diary; Don’t ignore new floaters or flashes.

2. Do wear sunglasses outdoors; Don’t sunbathe without UV protection.

3. Do maintain a healthy diet; Don’t rely on unregulated supplements.

4. Do exercise regularly; Don’t smoke or expose yourself to second-hand smoke.

5. Do follow up as recommended; Don’t skip routine eye exams.

6. Do report vision changes promptly; Don’t self-treat with over-the-counter eye drops.

7. Do ask about genetic testing if multiple lesions; Don’t assume CHRPE lesions always benign.

8. Do use blue-light filters for screens; Don’t overexpose eyes to bright devices.

9. Do stay hydrated; Don’t let chronic dehydration compromise ocular perfusion.

10. Do consult before starting any new therapy; Don’t take advice from non-medical sources.

---

Frequently Asked Questions

1. What is CHRPE?
   A benign, congenital RPE lesion, usually asymptomatic and stable.

2. Does CHRPE affect vision?
   Rarely—only if complicated by CNV or other secondary changes.

3. How is CHRPE diagnosed?
   Fundoscopy shows a flat, pigmented lesion; OCT and autofluorescence confirm RPE origin.

4. Is treatment ever needed?
   No specific treatment for CHRPE itself; only observe unless secondary complications arise.

5. Can CHRPE be malignant?
   No—it does not transform into melanoma, but can mimic other pigmented lesions.

6. Why monitor CHRPE?
   To detect any rare changes (growth, CNV) early and differentiate from other lesions.

7. Are multiple CHRPE lesions dangerous?
   They may signal FAP; warrants colonoscopy screening.

8. Can lifestyle change CHRPE?
   No, but healthy habits support overall retinal health.

9. When should I repeat imaging?
   Typically annually, or sooner if symptoms develop.

10. Can CHRPE recur after surgery?
    Surgery is not indicated; recurrence is not applicable.

11. Is CHRPE hereditary?
    The solitary form is sporadic; multiple lesions may have genetic linkage (FAP).

12. Do I need to take vitamins?
    Supplements support general eye health but do not treat CHRPE.

13. Can eye exercises help?
    They may improve ocular circulation but won’t change the lesion itself.

14. Is CHRPE linked to other eye diseases?
    Only via complications such as CNV, which is rare.

15. Where can I learn more?
    Consult an ophthalmologist or trusted resources like the American Academy of Ophthalmology.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: July 19, 2025.